LIVECAST Markets Briefs Calendar Search

Research

AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar Search AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive Account

Live News REGULATION FLASH L impact Sep 30, 2026, 09:45 AM UTC

German Federal Court confirms Celle court decision in favour of Porsche SE

4 billion euros.

SquawkNews Newsroom

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

PSHGP.DE

Related stories

The Zcash ETF completes 3-for-1 forward share split; NAV adjusts to $37.14 The Zcash ETF completed a 3-for-1 forward share split, increasing shares outstanding to 23,967,900 and reducing NAV per share to $37.14.Key Highlights:Original SEC Filing: Zcash ET L impact | REGULATION | Sep 30, 2026, 12:23 PM UTC ACM Research subsidiary reports RMB 17.1B backlog, 88% YoY rise ACM Research reported its Shanghai subsidiary's backlog of RMB 17.1 billion (USD $2.5 billion), up 88.2% year—over—year.Key Highlights:Original SEC Filing: ACM Research, Inc. [ ACM L impact | REGULATION | Sep 30, 2026, 12:13 PM UTC Celcuity launches REVTORPYK commercially in US for HR+/HER2- advanced breast cancer Celcuity announced REVTORPYK is now commercially available in the U.S. for eligible HR+/HER2- advanced breast cancer patients without a PIK3CA mutation.Key Highlights:Original SEC L impact | REGULATION | Sep 30, 2026, 12:13 PM UTC AEON Biopharma (AEON) Gets FDA Feedback Enabling Streamlined ABP-450 Path AEON received FDA Type 2b meeting minutes indicating prior head-to-head ABP-450 vs BOTOX studies may be used as supportive evidence, and plans an IND in Q4 2026 for a CMAP PD study L impact | REGULATION | Sep 30, 2026, 12:09 PM UTC AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450 FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging work L impact | REGULATION | Sep 30, 2026, 12:09 PM UTC Atara Biotherapeutics, Inc. (ATRA) Partner Resubmits Tab-cel BLA to FDA Atara said partner Pierre Fabre resubmitted the tabelecleucel (tab-cel) BLA to the FDA with additional patients and longer follow-up from the ALLELE study. Atara expects to provide L impact | REGULATION | Sep 30, 2026, 12:05 PM UTC

SQUAWK/NEWS

Live financial news for traders. Read the headline on screen or hear it through LiveCast while you stay on the trade.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

Product

Open LiveCast
Plans & Pricing
Institutional API
How LiveCast Works
Live Markets
Session Briefs
RSS Feed
Calendar
Search
Instrument directory

Research

Macro
Politics
Prediction Markets
AI Market Assistant
News Archive

For Traders

Market Movers
US Stocks
Why News Moves Markets
News for Traders
How to Trade the News
What Is an Audio Squawk?
Policy Calendar

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

Legal

Privacy Policy
Terms of Use

© 2026 SquawkNews SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.